EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet

Chetana Ahire, Rajesh Yadav, Utkarsh U Bhamare, Ginpreet Kaur, Mahesh B Palkar iD

The FASEB Journal · 31.03.2026 · 40 (6)

DOI: 10.1096/fj.202503317r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 18.03.2026. Verfasst von Chetana Ahire und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS University, Mumbai, Maharashtra, Indi…. Hauptthemen laut MEDLINE: Diet, Ketogenic, Neurodegenerative Diseases, Drug Resistant Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 153 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ketogenic diet (KD), a high‐fat, low‐carbohydrate intervention, is well established for drug‐resistant epilepsy and is increasingly explored in neurodegenerative disorders. KD reduces neuronal hyperexcitability through enhanced γ‐aminobutyric acid (GABA)ergic transmission and modulation of neurotransmitter balance, underlying its efficacy in refractory epilepsy. Beyond seizure control, emerging evidence suggests KD may influence disease processes in conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Huntington's disease. Preclinical studies indicate that KD can modulate mitochondrial bioenergetics, oxidative stress, neuroinflammation, neurotransmitter signaling, and gut‐brain interactions, though these effects are highly context‐dependent and primarily derived from cellular and animal models. Clinical data remain limited, heterogeneous, and short‐term, with small cohorts and variable outcome measures. Sustaining adherence and assessing long‐term safety remain significant challenges in patient populations. This review summarizes recent experimental and clinical findings, highlighting the molecular and cellular mechanisms through which KD exerts neuroprotective effects. We also evaluate translational evidence and discuss the potential utility of KD as an adjunctive intervention in neurological disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, KetogenicNeurodegenerative DiseasesDrug Resistant EpilepsyHumansAnimals

Stichwörter der Autor:innen

Alzheimer's diseaseHuntington's diseaseParkinson's diseaseamyotrophic lateral sclerosisdrug‐resistant epilepsyketogenic dietmultiple sclerosisneurodegeneration

Autor:innen und Institutionen

  • Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS University, Mumbai, Maharashtra, India.
  • Department of Pharmaceutical Chemistry, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS University, Mumbai, Maharashtra, India.

ORCID-Profile: Mahesh B Palkar

Zitieren

APA

Ahire, C., Yadav, R., Bhamare, U. U., Kaur, G., & Palkar, M. B. (2026). From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet. The FASEB Journal, 40(6). https://doi.org/10.1096/fj.202503317r

Vancouver

Ahire C, Yadav R, Bhamare UU, Kaur G, Palkar MB. From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet. The FASEB Journal. 2026;40(6). doi:10.1096/fj.202503317r

BibTeX
@article{Ahire2026,
  author = {Ahire, Chetana and Yadav, Rajesh and Bhamare, Utkarsh U and Kaur, Ginpreet and Palkar, Mahesh B},
  title = {From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {6},
  doi = {10.1096/fj.202503317r}
}
Kostenlos starten →